Cell and Gene Therapies Demand a Robust System
Miltenyi Biotec
Standardizing your CGT platform to ensure consistency during experiments is essential for improving future clinical outcomes
Around 65 percent of the wounds treated with Vyjuvek showed complete wound closure in DEB patients